GSK announces ViiV’s cabotegravir for HIV prevention gets positive CHMP opinion

GSK plc announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, welcomed a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, recommending marketing authorization for cabotegravir long-acting injectable and tablets for HIV prevention. Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis, or PrEP, to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kg.